Invokana 100 mg and 300mg film coated tablets
*Company:
A. Menarini Pharmaceuticals Ireland LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 28 June 2023
File name
IE-Invokana-Approved -June 2023-SmPC-clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4 - Diabetic ketoacidosis added
Section 4.5 - Lithium added
Updated on 28 June 2023
File name
NI & IE-Invokana-Approved-June 2023-PIL-clean.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Free text change information supplied by the pharmaceutical company
Section 2 - interactions with Lithium added
Updated on 15 June 2023
File name
Invokana SmpC Approved feb 23.pdf
Reasons for updating
- Previous version of SPC reinstated
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 13 June 2023
File name
Invokana SmpC Approved May 23 - Article 61-3 IE details.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 13 June 2023
File name
Invokana-PIL-clean Approved May 23.pdf
Reasons for updating
- New PIL for new product